ABSTRACT
INTRODUCTION
FDCs are fundamental constituent members of primary and secondary lymphoid follicles, which are located mainly in the lymph nodes, as well as extranodal sites [1] . Hyperplasia of FDCs occurs in a number of reactive and neoplastic conditions and the first characterized FDCS was depicted by Monda et al in 1986 [2] . In the 2008 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissue [3] , FDCS belongs to a separate category of histiocytic and dendritic cell neoplasms, among which histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma, and disseminated juvenile xanthogranuloma were also included. A definitive diagnosis may be obtained with pathological analysis and identification of positivity for CD21 and CD35 by immunohistochemical examination [4] , but the misdiagnosis is still easy to be made. No global landscape of CNVs has been identified for this tumor yet. Here, we present a case of FDCS and its genetic characteristics on OncoScan®gene kit test in a Chinese female and review the relevant literature.
CASE PRESENTATION
During a routine evaluation, the chest X-ray of a 44-year-old woman showed an asymptomatic right pulmonary hilar mass. The follow-up computed tomographic (CT) scan of the chest documented the presence of a 7.5cm×7.0cm mass. The contrast enhanced chest CT showed that a mass existed in the right pulmonary hilar region, which was well-circumscribed without predominant lobulated and spiculated sign, was www.impactjournals.com/oncotarget/ Vol.9, (No.1), Supplement 1, pp: s1317-s1324
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Oncotarget s1318 www.impactjournals.com/oncotarget slightly heterogeneous without calcification and was connected with the paravertebral pleura. It also showed enlarged lymph nodes in the pulmonary hilar and mediastinal region, including level 10, level 11, level 7 and level 4R, the largest of which was 1.8cm in diameter. All other physical and routine laboratory examination results were negative.
A CT-guided biopsy of the mass was performed and "mesenchymal tissue malignant tumors" was rendered. The remote consultation of pathology suspected "spindle cell cancer" and the immunohistochemistry (IHC) supported "synovial sarcoma". Another CT-guided biopsy was conducted and the diagnosis was revised to FDCS. Following the initial evaluation, the patient underwent a right pneumonectomy (Figure 1) .
Postoperative macroscopic pathology revealed that a 13×12×10cm 3 mass surrounded the right pulmonary trunk and pointed front-end branching roots, as well as infiltrated the intermediate bronchus, the root of superior lobar bronchus and visceral pleura. Microscopically, the neoplasm was highly cellular and arranged primarily in short, compact, intersecting storiform or whorling patterns ( Figure 2A ). The neoplastic cells were spindled to ovoid shape, with indistinct cell border and with light to abundant eosinophilic cytoplasm. The tumor cell nuclei were round to vesicular, with delicate membranes and a typical small central nucleoli, and intranuclear inclusions were found occasionally (Figure 2A, a) . Mitotic figures were 1~2 per 10 high power fields (HPF) and necrosis was suspected in some areas. Focal metastasis was found in the evaluated 37 peribronchial, mediastinal and hilar lymph nodes ( Figure 2B ). IHC demonstrated that the tumor cells were positive for CD21 ( Figure 2C ), CD35 ( Figure 2D ), fli-1, vimentin and D2-40 ( Figure 2E ). The cells were also suspiciously positive for CD99 and Bcl-2. The tumor cells failed to express CD3, CD17, CD20, CD23, CD30, CD31, CD34, CD45, CD56, CD68, CD1α, CK 8/18, CKPan, DOG-1, Desmin, EMA, GFAP, Pax-5, mum-1, SMA, S-100, Syn, and ALK/P(80). The ki-67 index was about 30% ( Figure 2F ). EBER was not identified in the tumor cells. Unfortunately, the patient died of sudden cardiac death within a week after the surgery (Figure 1) .
To further reveal the genomic characteristics of this rare neoplasm, a MIP chip array of OncoScan ® Assay Kit was used with paraffin-embedded (FFPE) samples. The raw data were analyzed and visualized by illumia' offical software OncoScan Console and BioDiscovery's Nexus Express. CNVs and the ploidy were mainly inferred by the segment distribution of probe log 2 ratios and B -allele frequencies (BAFs). We found that no SN variants were detected while the chip includes 900 cancer genes. The CN analysis showed a 41.58% genomic change which mainly presented as copy loss. In chr2, chr3, chr5, chr6, chr9, chr10, chr13, chr14, chr16, chr22 and chrX, loss of large segmentation and LOH were observed ( Figure 3 ). The involved oncogenes tracking from Cancer Gene Census were collected and explored one by one. We paid more attention to genes with exceptional CNVs comparing to the adjacent parts. Finally, by combining TCGA and literature review, we focused on the genes closely 
DISCUSSION
Here we report a rare neoplasm, which is the ninth case of primary pulmonary FDCS in English publication [5] [6] [7] [8] [9] [10] [11] (Table 1 ). In our case, the initial speculation was synovial sarcoma, which is composed of epithelial or spindle cells and is positive for EMA, CK, BCL-2, vimentin etc [12] . The intersecting storiform, existence of epithelioid cells and suspicious positive for CD99 and BCL2 confused the pathologist, but the negative expression for CD21 and CD35 helped us make exclusive diagnosis. Other confusable tumors include interdigitating dendritic cell sarcoma (IDCS), ectopic meningioma, ectopic thymoma, malignant fibrous histiocytoma, inflammatory pseudotumor, malignant peripheral nerve sheath tumor, angiosarcoma or hemangioendothelioma, lymphoepithelioma-like sarcoma, malignant melanoma, gastrointestinal stromal tumor and soft tissue sarcoma [13] . The rareness of this disease and the lack of specific clinical and imaging features make it easy to misdiagnose, but it is just the first reason. The second is that the key to differential diagnosis is IHC. However, it needs a high index of suspicion and can be achieved only conditionally. If the pivotal targets were not tested, the misdiagnosis would be made. Then we explored the genomic characteristics of this tumor, which may be helpful to make diagnosis, just like the BCR-ABL1 for Chronic myelogenous leukaemia and PDGFRA, PDGFRB or FGFR1 for myeloid and lymphoid neoplasms [3] .
The largest pooled analysis was performed in 2013 by Saygin et al. [14] , which illustrated demographics, pathological characteristics and clinical features of patients with this rare tumor. However, no genetic abnormalities have been identified as defining this tumor. Some efforts have been made in this respect. Perry AM et al. [15] summarized the cytogenetic findings on FDCS but confirmed no consistent or specific aberration. Starr JS et al. [16] first characterized DNA mutations in this disease and found three gene mutations: PTEN, RET and TP53. Heounjeong Go et al. [17] found that FDCS exhibited a 18.5% (5 in 27 cases) rate of BRAF mutation, which hints that BRAF pathway may make a contribute to the pathogenesis of this disease. Sylvia Hartmann et al. [18] divided FDCS into two subgroups by high and low miRNA expression levels while they did no difference on BRAF mutation status. By targeted genomic sequencing of FDCS, Gabriel K Griffin et al. [19] revealed recurrent loss-of-function alterations of NFKBIA, CYLD, CDKN2A and RB1, which were involved in NF-κB regulatory pathway (5 of 13 cases, 38%) and cell cycle progression (4 of 13 cases, 31%). Moreover, they also found focal copy number gain of chromosome 9p24 (3 of 13 cases, 23%) that contains the genes CD274 (PD-L1) and PDCD1LG2 (PD-L2), which are involved in immune evasion in cancer. Wenting Huang et al. [20] maintained that there is a high frequency of clonal IG and T-cell receptor gene rearrangements in FDCS. Luisa Lorenzi et al. [21] pointed out two markers, FDCSP and SRGN, by whole transcriptome sequencing. Maria Antonella Laginestra et al. [22] indicated that the mRNA expression levels of PD-1, PD-L1 and PD-L2 are higher than other MTs comparing to FDCS. Differing from the previous study, our case is the first case using whole-gene chip to study the global landscape of gene characteristics and we focused on the CNVs in this tumor. In the meantime, we dug into the involved genes and aimed to find some functional members. REL locates at chromosome 2p13-p12. According to the segmentation analysis, LOH was detected in this region while CN loss was detected in adjacent regions, suggesting the amplification of REL. In solid tumors, amplification of genes may be related to regulate cell proliferation or drug resistance [23] . REL is the most frequently amplified gene in germinal center (GC) derived B cell lymphoma, including GC DLBCL, follicular lymphoma and classical Hodgkin disease [24] and it shows amplification in 23% DLBC in TCGA. This gene encodes a member of the REL/nuclear factor-kB(REL/ NF-kB) family of transcription factors, which act on cell growth, differentiation and survival regulation, especially in hematopoietic lineages [24] . One recent study found several recurrent somatic alterations in FDCS, which involve in the negative regulation of NF-kB activation [19] . Our result infers another possible mechanism of NF-κB activation, hinting the vital role of REL in this neoplasm. TET2 locates at chromosome 10q24. In this gene, a part of it is amplification while the adjacent parts were CN loss, suggesting the possibility of the loss of function. In 2009, TET2 was first discovered in myeloid malignancies, such as myelodysplastic syndrome(MDS) [25] , chronic myelomonocytic leukemia(CMML) [26] , acute myeloid leukemia (AML) [27] , and myeloproliferative neoplasms(MPN) [28] . Then, recurrent mutation was found in subtypes of mature T/NE-cell neoplasms such as mature B-cell lymphoma, diffuse large B-cell lymphoma. Somatic TET2 mutations cause impairment of activity of the TET2 dioxygenase and the CNV of this gene in our case may also lead to the loss of function, resulting in the failure of 5-mC to 5-hmC conversion, and eventually the failure of demethylation [29] . CREBBP locates at 16p13.3. CN loss was detected in this region and part of CREBBP has more loss comparing to the adjacent genes, hinting the homozygous deletion of this gene. CREBBP is one of the most frequently mutated chromatin modifying gene in FL and DLBCL, second to KMT2D [30] . This gene encodes the transcriptional coactivator and histone acetyltransferase CREB-binding protein. Any type of loss of function impairs histone acetylation and transcriptional regulation of CREBBP targets [31] . Loss-of-function CREBBP mutations in FL has been shown to assist evasion by down regulating MHC class II expression along with reducing T cell infiltration [32] . Furthermore, patients carrying CREBBP mutation tend to have high risks because of acetylation imbalance. CYLD locates at 16q12. Homozygous deletion was found in this region. CYLD was originally identified in familial cylindromatosis(Brooke-Spiegler syndrome) and was linked to pathogenesis of several tumors, such as melanoma, T-cell acute lymphoblastic leukemia, colon carcinoma and hepatocellular carcinoma [33] . CYLD is a negative regulator of NF-κB and Wnt/β-catenin signaling, and loss of CYLD by deletion or mutations may sensitize cells to NF-κB-stimuli and Wnt ligands [33] .
There lie some limitations in our study. The first one is from the intrinsic defect of the OncoScan FFPE Assay Kit. This kit has extremely high sensitivity and specificity in CNVs detection, but there still are a small number of SMs that could not be reliably validated [34] , and chromosome balanced translocation and chromosome inversion cannot be detected. Besides, unfortunately the patient died three days after surgery which leads to the lack of treatment information about this tumor. Moreover, the only case restricts our result reproducing. Nevertheless, the significance from our case remains to mention. We found some crucial genes by bioinformatics and literature review, which have important influence on the fate of the neoplasm and can be latent therapy targets. For this rare and under-recognized tumor, it is the first time to raise the genetic testing method for diagnosis.
In summary, the impactful therapeutic intervention requires a global understanding of the genomic mutations that drive tumor occurrence and development. For this reason, the whole genetic testing combining with bioinformatics' analysis bulks large, especially for the rare neoplasm because the number of cases from one or several institutions is usually small. Only in this way can we have a perfect management for this tumor.
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